NasdaqGS - Nasdaq Real Time Price USD

uniQure N.V. (QURE)

15.15
+0.44
+(2.99%)
As of 2:45:45 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
20,201
27,119
15,843
106,483
524,002
Cost of Revenue
9,298
18,327
13,628
3,343
24,976
Gross Profit
10,903
8,792
2,215
103,140
499,026
Operating Expense
176,935
189,721
284,544
247,062
188,408
Operating Income
-166,032
-180,929
-282,329
-143,922
310,618
Net Non Operating Interest Income Expense
-43,719
-42,326
-21,995
-11,095
-7,312
Other Income Expense
-5,555
-13,872
-2,233
26,798
29,500
Pretax Income
-215,306
-237,127
-306,557
-128,259
332,806
Tax Provision
2,269
2,429
1,921
-1,470
3,217
Net Income Common Stockholders
-217,575
-239,556
-308,478
-126,789
329,589
Diluted NI Available to Com Stockholders
-217,575
-239,556
-308,478
-126,789
329,589
Basic EPS
-4.38
-4.92
-6.47
-2.71
7.17
Diluted EPS
-4.38
-4.92
-6.47
-2.71
7.04
Basic Average Shares
49,830.65
48,649.13
47,670.99
46,735.05
45,986.47
Diluted Average Shares
49,830.65
48,649.13
47,670.99
46,735.05
46,840.97
Total Operating Income as Reported
-169,397
-184,294
-282,871
-143,159
310,618
Rent Expense Supplemental
--
1,358
900
820
--
Total Expenses
186,233
208,048
298,172
250,405
213,384
Net Income from Continuing & Discontinued Operation
-217,575
-239,556
-308,478
-126,789
329,589
Normalized Income
-215,042.55
-230,852.34
-306,369.24
-152,525.61
300,374.16
Interest Income
19,034
21,415
19,562
609
162
Interest Expense
62,753
63,741
41,557
11,704
7,474
Net Interest Income
-43,719
-42,326
-21,995
-11,095
-7,312
EBIT
-152,553
-173,386
-265,000
-116,555
340,280
EBITDA
-138,014
-160,745
-253,100
-108,018
347,579
Reconciled Cost of Revenue
9,298
7,796
3,779
3,343
24,976
Reconciled Depreciation
14,539
12,641
11,900
8,537
7,299
Net Income from Continuing Operation Net Minority Interest
-217,575
-239,556
-308,478
-126,789
329,589
Total Unusual Items Excluding Goodwill
-3,413
-11,730
-2,842
26,035
29,500
Total Unusual Items
-3,413
-11,730
-2,842
26,035
29,500
Normalized EBITDA
-134,601
-149,015
-250,258
-134,053
318,079
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-880.55
-3,026.34
-733.24
298.39
285.16
12/31/2021 - 2/5/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

RGNX REGENXBIO Inc.
9.90
+1.12%
 
SLDB Solid Biosciences Inc.
2.9000
0.00%
 
LXEO Lexeo Therapeutics, Inc.
3.4500
+4.86%
 
SRRK Scholar Rock Holding Corporation
31.05
+2.95%
 
ITOS iTeos Therapeutics, Inc.
8.39
-0.25%
 
CYTK Cytokinetics, Incorporated
32.47
+5.60%
 
SGMO Sangamo Therapeutics, Inc.
0.4998
+0.26%
 
RCKT Rocket Pharmaceuticals, Inc.
6.64
+2.95%
 
JANX Janux Therapeutics, Inc.
25.55
+5.71%
 
TVTX Travere Therapeutics, Inc.
17.51
+2.94%